6.80
0.38 (5.92%)
| 前收盘价格 | 6.42 |
| 成交量 | 291,808 |
| 预期市盈率 (P/E Forward) | 3.33 |
| 价格/销量 (P/S) | 60.63 |
| 股市价格/股市净资产 (P/B) | 1.13 |
| 52周波幅 |
| 营业毛利率 | 14.39% |
| 营业利益率 (TTM) | -105.99% |
| 稀释每股收益 (EPS TTM) | 0.580 |
| 季度收入增长率 (YOY) | -65.20% |
| 总债务/股东权益 (D/E MRQ) | 13.66% |
| 流动比率 (MRQ) | 21.88 |
| 营业现金流 (OCF TTM) | -54.55 M |
| 杠杆自由现金流 (LFCF TTM) | -65.48 M |
| 资产报酬率 (ROA TTM) | 0.51% |
| 股东权益报酬率 (ROE TTM) | 7.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Entrada Therapeutics, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -3.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.88 |
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 12.36% |
| 机构持股比例 | 80.37% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mpm Asset Management Llc | 30 Sep 2025 | 4,381,062 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| DOSHI DIPAL | - | 7.30 | -8,724 | -63,685 |
| DOWDEN NATHAN J | - | 7.30 | -2,528 | -18,454 |
| MPM BIOVENTURES 2014, L.P. | - | 7.15 | -130,741 | -932,460 |
| MPM BIOVENTURES 2018, L.P. | - | 7.15 | -130,741 | -932,460 |
| SETHURAMAN NATARAJAN | - | 7.30 | -2,079 | -15,177 |
| WENTWORTH KORY JAMES | - | 7.30 | -1,733 | -12,651 |
| 累积净数量 | -276,546 | |||
| 累积净值 ($) | -1,974,887 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 7.20 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2014, L.P. | 03 Sep 2026 | 卖 (-) | 32,263 | 7.17 | 231,326 | |
| MPM BIOVENTURES 2018, L.P. | 03 Sep 2026 | 卖 (-) | 32,263 | 7.17 | 231,326 | |
| WENTWORTH KORY JAMES | 职员 | 02 Sep 2026 | 处理 (-) | 1,733 | 7.30 | 12,651 |
| SETHURAMAN NATARAJAN | 职员 | 02 Sep 2026 | 处理 (-) | 2,079 | 7.30 | 15,177 |
| DOWDEN NATHAN J | 职员 | 02 Sep 2026 | 处理 (-) | 2,528 | 7.30 | 18,454 |
| DOSHI DIPAL | 职员 | 02 Sep 2026 | 处理 (-) | 8,724 | 7.30 | 63,685 |
| MPM BIOVENTURES 2014, L.P. | 02 Sep 2026 | 卖 (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2018, L.P. | 02 Sep 2026 | 卖 (-) | 25,131 | 7.30 | 183,456 | |
| MPM BIOVENTURES 2014, L.P. | 01 Sep 2026 | 卖 (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2018, L.P. | 01 Sep 2026 | 卖 (-) | 29,088 | 7.07 | 205,652 | |
| MPM BIOVENTURES 2014, L.P. | 31 Aug 2026 | 卖 (-) | 44,259 | 7.05 | 312,026 | |
| MPM BIOVENTURES 2018, L.P. | 31 Aug 2026 | 卖 (-) | 44,259 | 7.05 | 312,026 | |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合